ALFA FinderBSE filing, NSE: EMCURE. Summary written from the filing by ALFA Finder's alert engine.
Emcure Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,212.80
- Market cap
- ₹41,979 Cr
- Revenue (annual)
- ₹9,204 Cr
- Net profit (annual)
- ₹924.4 Cr
- P/E (TTM)
- 38.4×Sector 43.0×
- Promoter holding
- 77.82%-0.01% QoQ
- FII holding
- 4.94%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emcure Pharmaceuticals Ltd
All →Emcure Pharmaceuticals Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹2,820 Cr (+24%) and PAT ₹325 Cr (+29%) were strong. FY27 revenue growth guidance raised to above 20%. Net debt rose ₹263 Cr on acquisition payouts. FY28 guidance withheld.
- Call
- Guides 20% growth
Emcure Pharmaceuticals Investor Presentation: Key Takeaways
Q2FY27 revenue INR 28,205 Mn (+24.3% YoY), EBITDA INR 5,748 Mn (20.4% margin, +103 bps), PAT INR 3,251 Mn (+29.3%). International-led growth; net debt rose on acquisition payments.
Emcure Pharmaceuticals Q2 FY27 Results: Net Profit ₹325.1 Cr, Up 29.3% YoY
Emcure Pharmaceuticals Ltd reported revenue from operations of ₹2,820 Cr (+24.3% YoY) and net profit of ₹325.1 Cr (+29.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹325.1 Cr · +29.3% YoY
Emcure Pharmaceuticals Other Announcement
Emcure Pharmaceuticals submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory compliance disclosure under SEBI.
Emcure Pharmaceuticals Board Meeting Date
Emcure Pharmaceuticals will hold a board meeting on November 03, 2026, to consider and approve the company's standalone and consolidated financial results for the quarter.
Emcure Pharmaceuticals Acquisition
Emcure Pharmaceuticals approved the merger of its wholly-owned subsidiaries, Zuventus Healthcare and Emcutix Biopharmaceuticals, into itself. The internal restructuring involves no cash consideration or share issuance.
Other annual report announcements
All →Vineet Laboratories Annual Report
Vineet Laboratories filed its FY 2025-26 Annual Report, which marks its turnaround and recapitalisation year. The AGM is scheduled for 30 November 2026.
Indrayani Biotech Annual Report
Indrayani Biotech has filed its 34th Annual Report for FY2025-26, containing the AGM notice for 30 November 2026 by VC/OAVM. The chairman notes a Rights Issue was initiated in October 2026 to raise capital.
ESDS Software Solution Annual Report
ESDS Software Solution submitted its FY2025-26 Annual Report along with the AGM notice. The AGM is on 30 November 2026 via VC/OAVM, with remote e-voting.
The Orissa Minerals Development Company Annual Report
Orissa Minerals Development Company filed its FY 2025-26 Annual Report and 108th AGM notice, with the AGM set for 30 November 2026. The filing is a Regulation 34 intimation with no transaction or financial event.
Viksit Engineering Annual Report
Viksit Engineering filed its 44th Annual Report for FY 2025-26 with BSE. The report includes notice of the AGM on 30 November 2026.
Innovision Annual Report
Innovision Ltd filed its FY2025-26 Annual Report with the notice of its 20th AGM, scheduled for 5 December 2026 via VC/OAVM. The notice covers financial statements, a director re-appointment and a non-executive director regularisation.